drugset / Trial / NCT03477539
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well daratumumab works in treating transplant-eligible patients with multiple myeloma. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Timeline
- Start
- 2018-04-09
- Primary completion
- 2022-05-11
- Completion
- 2025-03-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | Intravenous |
| Background | Lenalidomide | Other / unclassified | — | Oral |